Today's Trend
Adicet Bio, Inc. (NASDAQ:ACET) — shares have moved higher today after several analyst upgrades and coverage changes; below are investor-focused takeaways on recent news that likely drove the move and could influence near-term trading.
- HC Wainwright raised near-term and full-year 2026 EPS forecasts (Q1–Q4 and FY), trimming projected losses (e.g., Q1 est. now ($2.80) vs prior ($2.91); FY2026 now ($11.58) vs ($12.17)) and reiterated a "Buy" rating with a $27 price target — signals improved analyst sentiment and a large implied upside versus the current share price. MarketBeat HC Wainwright Coverage
- Zacks upgraded ACET to a Zacks Rank #2 (Buy), citing improving earnings prospects — upgrades from recognized research services can attract buying interest and short-term momentum. Adicet Bio (ACET) Upgraded to Buy: Here's Why
- Reported short-interest data for March shows anomalous "0 shares" and NaN changes across multiple filings — the numbers appear unreliable or misreported, so there is no clear evidence of elevated short pressure based on the available data. (Monitor future filings for corrected short-interest figures.)
- An AmericanBankingNews headline framed HC Wainwright's coverage as a "pessimistic forecast" for ACET stock price — conflicting media spin can add volatility even when analyst estimates are being trimmed toward smaller losses. HC Wainwright Issues Pessimistic Forecast for Adicet Bio (NASDAQ:ACET) Stock Price
Bottom line for investors: analyst upgrades (HC Wainwright + Zacks) are the primary positive catalysts behind today's uptick — they signal a modestly improved outlook and highlight large implied upside from the $27 target — but reported short-interest anomalies and mixed media framing add uncertainty. Watch upcoming clinical/operational updates and corrected short-interest filings for clearer directional drivers.